Ramucirumab is an antivascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) fully human monoclonal IgG1 antibody that inhibits tumor growth by blocking the interaction of VEGFR2 with its natural ligand.7 This evidence concerns the gene KDR and neoplasm.